Calculation Tables. Olerup SSP Kits without Taq Polymeras

Similar documents
Calculation Tables. Olerup SSP Kits without Taq Polymeras

ASHI Proficiency Testing Program Summary Report. Survey 2013-HT1 / HLA Typing

The Human Major Histocompatibility Complex

STEP-programme S-candiaT-ransplant kidney E-xchange P-rogramme (STEP) Version 1.8

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director

Evaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group

2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center

OPTN/UNOS Policy Notice Review of HLA Tables (2016)

Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005)

Diversity and Frequencies of HLA Class I and Class II Genes of an East African Population

HLA Mismatches. Professor Steven GE Marsh. Anthony Nolan Research Institute EBMT Anthony Nolan Research Institute

DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS

Validation of the MIA FORA NGS FLEX Assay Using Buccal Swabs as the Sample Source

Supporting Information

Documentation of Changes to EFI Standards: v 5.6.1

The MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK

Significance of the MHC

AG MHC HLA APC Ii EPR TAP ABC CLIP TCR

CPT Codes for Pharmacogenomic Tests

HLA and new technologies. Vicky Van Sandt

A clear path forward AVAILABLE NOW THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

FONS Nové sekvenační technologie vklinickédiagnostice?

Historical definition of Antigen. An antigen is a foreign substance that elicits the production of antibodies that specifically binds to the antigen.

IMMUNOLOGY. Elementary Knowledge of Major Histocompatibility Complex and HLA Typing

National Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants

How to Find an Unrelated Donor Theory & Technology

A clear path forward COMING SOON THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS

Allele and Haplotype Frequencies of Human Leukocyte Antigen-A, -B, -C, -DRB1, and -DQB1 From Sequence- Based DNA Typing Data in Koreans

Immunogenetics in SARS: a casecontrol

Treatment of Chronic Antibody Mediated Rejection

EBMT2008_1_21:EBMT :06 Pagina 46 * CHAPTER 3. Immunogenetics of allogeneic HSCT * 3.1. The role of HLA in HSCT. J.M.

Supplementary Figure 1 Dosage correlation between imputed and genotyped alleles Imputed dosages (0 to 2) of 2-digit alleles (red) and 4-digit alleles

10/18/2012. A primer in HLA: The who, what, how and why. What?

Virtual Crossmatch in Kidney Transplantation

MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH

Significance of the MHC

21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com

Cover Page. The handle holds various files of this Leiden University dissertation.

CHAPTER 3 LABORATORY PROCEDURES

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

HLA-DQA1 and DQB1 Genotyping in Individuals with Family History of Gastritis

Significance of the MHC

Human Leukocyte Antigens and donor selection

The Major Histocompatibility Complex (MHC)

New trends in donor selection in Europe: "best match" versus haploidentical. Prof Jakob R Passweg

Minutes Tissue Typers Meeting Aarhus, 21st September 2018

Patient and Partner Consult Report

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex

6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?

Annual Report HISTOCOMPATIBILITY. and IMMUNOGENETICS

Relationship Between HLA-DMA, DMB Alleles and Type 1 Diabetes in Chinese

Prediction and Prevention of Type 1 Diabetes

10/7/ Immediate Action, Quest Diagnostics Nichols Institute, Valencia

HOST-PARASITE INTERPLAY

Marcelo Fernandez Vina Conflict of Interest: Co-Founder Sirona Genomics

Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale

Recent Research Advances in Drug Induced Liver Injury

Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos

Transplantation and Cancer

Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated

AmoyDx TM BRAF V600E Mutation Detection Kit

Basel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva

attomol HLA-B*27-Realtime LT 2 Assay for the detection of the human HLA-B*27-locus using LightCycler (Do not use for tissue typing!

BDC Keystone Genetics Type 1 Diabetes. Immunology of diabetes book with Teaching Slides

RealLine Mycoplasma genitalium Str-Format

PCR Starter Kit. For MiniAmp and MiniAmp Plus PCR systems USER GUIDE USER GUIDE. Part. No Revison C.0

Profiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009

HLA Disease Associations Methods Manual Version (July 25, 2011)

Osteoclast Culture Kit

Effects of age-at-diagnosis and duration of diabetes on GADA and IA-2A positivity

Genetic Testing for Pharmacogenetics

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection

The Relationship between Minor Histocompatibility Antigens and Graft Versus Host Disease in Unrelated Peripheral Blood Stem Cell Transplants

Implementation Inoculate positive Alicyclobacillus sample from BAT-Agar into incubation tube (Fig 1) with induction broth.

Genotyping of HLA-class-I and II by PCR-SSP of Patients with. Recurrent Aphthous Stomatitis

STANDARD CONNECTORS. ENFIT CONNECTORS. EITHER WAY, WE KEEP YOU CONNECTED.

OU Human Physiology: Transplantation and Cancer Immunology *

ASSESSMENT OF THE RISK FOR TYPE 1 DIABETES MELLITUS CONFERRED BY HLA CLASS II GENES. Irina Durbală

Clinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017

HLA AND KIR GENE POLYMORPHISM IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

Use of PCR with Sequence-specific Primers for High-Resolution Human Leukocyte Antigen Typing of Patients with Narcolepsy

T-cell receptor feature. Antibody/antigen interaction. Major Histocompatibility Complex. Antigen processing. Antigen presentation

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Osteoclast Culture Kit

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Samples Available for Recipient and Donor

Protocol. Preparation Protocol for the Target-Ready Vevo MicroMarker Contrast Agent

Building and validating a prediction model for paediatric type 1 diabetes risk using next generation targeted sequencing of class II HLA genes

α chain β chain C N C N β 2 α 1 β 1 α 2

HLA Association in SLE patients from Lahore-Pakistan

HLA-C, DRB1 and DQB1 alleles involved in genetic predisposition to psoriasis vulgaris in the Slovak population

altona RealStar Instructions for Use RealStar CMV PCR Kit /2017 EN DIAGNOSTICS

Run glycans up to 5x faster than HILIC

HLA Class II Allele and Haplotype Frequencies in Iranian Patients with Acute Myelogenous Leukemia and Control Group

Alleles: the alternative forms of a gene found in different individuals. Allotypes or allomorphs: the different protein forms encoded by alleles

Patient Consult Report

HLA Class I and II Genotyping by PCR-SSO in Patients with Type-1 Diabetes Mellitus

HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis

Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset

Transcription:

Calculation Tables lerup SSP Kits without Taq Polymeras

Table 1: Volumes of the components needed per test for different numbers of when using Master Mix without. The recommended volumes listed below include volume to compensate for pipette variations and for losses of liquid on the interior walls of the tubes. per test Master mix (μl) sample (μl) (μl) taq polymerase (μl) 2 12 8 19.7 0.3 3 15 10 24.6 0.4 4 18 12 29.5 0.5 5 21 14 34.4 0.6 6 24 16 39.4 0.6 7 27 18 44.2 0.8 8 30 20 49.2 0.8 9 33 22 54.1 0.9 10 36 24 59 1.0 11 39 26 63.9 1.1 12 42 28 68.9 1.1 13 45 30 73.8 1.2 14 48 32 78.7 1.3 15 51 34 83.6 1.4 16 54 36 88.6 1.4 17 60 40 98.4 1.6 18 63 42 103.3 1.7 19 66 44 108.2 1.8 20 69 46 113.2 1.8 21 72 48 118.1 1.9 22 75 50 123 2.0 23 78 52 127.9 2.1 24 81 54 132.8 2.2 25 87 58 142.7 2.3 26 90 60 147.6 2.4 27 93 62 152.5 2.5 28 96 64 157.4 2.6 29 99 66 162.4 2.6 30 102 68 167.3 2.7 31 105 70 172.2 2.8 32 108 72 177.1 2.9 36 126 84 206.6 3.4 40 138 92 226.3 3.7 44 150 100 246 4.0 48 162 108 265.7 4.3 52 174 116 285.4 4.6 56 186 124 305 5.0 60 198 132 324.7 5.3 64 210 140 344.4 5.6 68 228 152 373.9 6.1 72 240 160 393.6 6.4 76 252 168 413.3 6.7 80 264 176 433 7.0 84 276 184 452.6 7.4 88 288 192 472.3 7.7 92 300 200 492 8.0 96 312 208 511.7 8.3 Table 2: Volumes of the components needed per test for different lerup SSP products when using Master Mix () including. The recommended volumes listed below include volume to compensate for pipette variations and for losses of liquid on the interior walls of the tubes. LW RESLUTIN KITS AND CMBI TRAYS name + + HLA - A HLA-A low 3E4 32 108 72 177,1 2,9 360 HLA - A HLA-A low Screening 82Y 24 81 54 132,8 2,2 270 HLA - B HLA-B low 3F8 64 210 140 344,4 5,6 700 HLA - B HLA-B low Screening 8E4 48 162 108 265,7 4,3 540 HLA - C HLA-C low 3F9 32 108 72 177,1 2,9 360 HLA - C HLA-C low Screening 2G0 24 81 54 132,8 2,2 270 HLA - DR DR low 1E5 32 108 72 177,1 2,9 360 HLA - DR DR low Screening 4E9 24 81 54 132,8 2,2 270 HLA - DQ DQ low 9F7 16 54 36 88,6 1,4 180 Combi A-B-DR 9F4 96 312 208 511,7 8,3 1040 A-B-C 8F0 96 312 208 511,7 8,3 1040 A-B-DR-DQ 6F9 96 312 208 511,7 8,3 1040 DQ-DR 6F5 47 162 108 265,7 4,3 540 DQA-DQB-DR Enhanced 5F0 96 312 208 511,7 8,3 1040

HIGH RESLUTIN KITS HIGH RESLUTIN KITS name + + name + + HLA-A HLA-A*01 1E6 56 186 124 305 5 620 HLA-A*02 8F9 96 312 208 511,7 8,3 1040 HLA-A*03 6F4 64 210 140 344,4 5,6 700 HLA-A*23 0G9 36 126 84 206,6 3,4 420 HLA-A*24 3F1 96 312 208 511,7 8,3 1040 HLA-A*25 8D7 16 54 36 88,6 1,4 180 HLA-A*26 1F3 48 162 108 265,7 4,3 540 HLA-A*34 87Y 12 42 28 68,9 1,1 140 HLA-A*66 9E5 16 54 36 88,6 1,4 180 HLA-A*11 4E7 64 210 140 344,4 5,6 700 HLA-A*29 9F9 28 96 64 157,4 2,6 320 HLA-A*30 45Y 32 108 72 177,1 2,9 360 HLA-A*31 4F2 40 138 92 226.3 3.7 460 HLA-A*32 5E4 30 102 68 167,3 2,7 340 HLA-A*33 7F1 32 108 72 177,1 2,9 360 HLA-A*74 1G7 16 54 36 88,6 1,4 180 HLA-A*80 5F3 5 21 14 34,4 0,6 70 HLA-A*36 8F7 8 30 20 49,2 0,8 100 HLA-A*68 4E1 48 162 108 265,7 4,3 540 HLA-A*69 0G8 6 24 16 39,4 0,6 80 HLA-B HLA-B*51 7E5 83 276 184 452,6 7,4 920 HLA-B*52 0G1 21 72 48 118,1 1,9 240 HLA-B*07 4F6 89 300 200 492 8.0 1000 HLA-B*08 3E6 48 162 108 265,7 4,3 540 HLA-B*44 8F4 64 210 140 344,4 5,6 700 HLA-B*45 0G4 16 54 36 88,6 1,4 180 HLA-B*13 9E7 31 105 70 172,2 2,8 350 HLA-B*14 9F8 22 75 50 123 2 250 HLA-B*15 3F7 96 312 208 511,7 8,3 1040 HLA-B*38 6F7 30 102 68 167,3 2,7 340 HLA-B*39 9F5 44 150 100 246 4 500 HLA-B*57 7E2 32 108 72 177,1 2,9 360 HLA-B*58 7E4 31 105 70 172,2 2,8 350 HLA-B*18 8F2 38 132 88 216,5 3,5 440 HLA-B*54 7E8 22 75 50 123 2 250 HLA-B*55 9E2 32 108 72 177,1 2,9 360 HLA-B HLA-B*56 0F3 24 81 54 132,8 2,2 270 HLA-B*27 5F4 47 162 108 265,7 4,3 540 HLA-B*35 2E1 93 300 200 492 8 1000 HLA-B*40 5F8 95 312 208 511,7 8,3 1040 HLA-B*37 7F5 30 102 68 167,3 2,7 340 HLA-B*41 2F6 24 81 54 132,8 2,2 270 HLA-B*42 3E7 16 54 36 88,6 1,4 180 HLA-B*46 8E3 24 81 54 132,8 2,2 270 HLA-B*47 4F9 11 39 26 63,9 1,1 130 HLA-B*48 8E2 20 69 46 113,2 1,8 230 HLA-B*49 4E8 21 72 48 118,1 1,9 240 HLA-B*50 7F3 24 81 54 132,8 2,2 270 HLA-B*53 5E5 24 81 54 132,8 2,2 270 HLA-B*59 4F0 10 36 24 59 1 120 HLA-B*67 7F8 8 30 20 49,2 0,8 100 HLA-B*73 80Y 4 51 34 83,6 1,4 170 HLA-B*78 1G6 16 54 36 88,6 1,4 180 HLA-B*81 8E6 10 36 24 59 1 120 HLA-B*82 2E6 6 24 16 39,4 0,6 80 HLA-C HLA-C*03 6E9 58 186 124 305 5 620 HLA-C*04 0F2 64 210 140 344,4 5,6 700 HLA-C*05 0E3 36 126 84 206,6 3,4 420 HLA-C*06 2E9 57 186 124 305 5 620 HLA-C*07 7E6 94 312 208 511,7 8,3 1040 HLA-C*01 2E2 32 108 72 177,1 2,9 360 HLA-C*02 2E7 42 150 100 246 4 500 HLA-C*08 61Y 32 108 72 177,1 2,9 360 HLA-C*12 1F8 48 162 108 265,7 4,3 540 HLA-C*14 3F4 31 105 70 172,2 2,8 350 HLA-C*15 1D5 38 132 88 216,5 3,5 440 HLA-C*16 7E1 24 81 54 132,8 2,2 270 HLA-C*17 1E9 16 54 36 88,6 1,4 180 HLA-C*18 8F3 8 30 20 49,2 0,8 100 HLA-C direct to high resolution for frequent alleles 0F2 96 312 208 511,7 8,3 1040

HIGH RESLUTIN KITS SCREENING KITS FR DISEASE ASSCIATED HLA ALLELES name + + name + + HLA-DR DRB1*01 9E8 24 81 54 132,8 2,2 270 DRB1*15 2F2 32 108 72 177,1 2,9 360 DRB1*16 7F0 16 54 36 88,6 1,4 180 DRB1*03 8E7 32 108 72 177,1 2,9 360 DRB1*04 3F5 48 162 108 265,7 4,3 540 DRB1*11 7F2 48 162 108 265,7 4,3 540 DRB1*13 1F6 58 198 132 324.7 5.3 660 DRB1*14 3F6 48 162 108 265,7 4,3 540 DRB1*07 3E8 22 75 50 123 2 250 DRB1*08 2F0 24 81 54 132,8 2,2 270 DRB1*12 6F1 24 81 54 132,8 2,2 270 DRB1*09 5F9 15 51 34 83,6 1,4 170 DRB1*10 6F8 8 21 14 34,4 0,6 70 DRB3 7F6 46 156 104 255,8 4,2 520 DRB4 3D3 14 48 32 78,7 1,3 160 DRB5 5F2 19 66 44 108,2 1,8 220 DRA 52F 2 12 8 19,7 0,3 40 HLA-DQ DQB1*05 1F7 32 108 72 177,1 2,9 360 DQB1*06 5E8 64 210 140 344,4 5,6 700 DQB1*02 98Y 24 81 54 132,8 2,2 270 DQB1*03 6F6 64 210 140 344,4 5,6 700 DQB1*04 5E2 19 66 44 108,2 1,8 220 DQB1 direct to high resolution for frequent alleles 2F4 96 312 208 511,7 8,3 1040 DQA1 3F0 32 108 72 177,1 2,9 360 HLA-DP DPB1 7F7 96 312 208 511,7 8,3 1040 DPA1 2E0 16 54 36 88,6 1,4 180 HLA-B B*27 unit dose 5F1 2 12 8 19,7 0,3 40 HLA-DQ NULL ALLELE KITS HLA-B*57:01 5E0 23 78 52 127,9 2,1 260 HLA-B*51,52 7F9 3 15 10 24,6 0,4 50 DQB1*06:02, DQA1*01:02 DQA1*02,05; DQB1*02,03:02 name 1E7 8 30 20 49,2 0,8 100 6F0 22 75 50 123 2 250 + + HLA-A HLA-A*24:09N 2E4 3 15 10 24,6 0,4 50 HLA-B HLA-B*51:11N 4F3 3 15 10 24,6 0,4 50 HLA-C HLA-C*04:09N 5F7 3 15 10 24,6 0,4 50 HLA-DR DRB4*01:03:01:02N 6F3 3 15 10 24,6 0,4 50 DRB5*01:08N 5F6 3 15 10 24,6 0,4 50

ADD-NS name + + HLA-A HLA-A*11 add-on 0G5 3 15 10 24,6 0,4 50 HLA-A*23 add-on 8F8 4 18 12 29,5 0,5 60 HLA-A*01 add-on 0E6 3 15 10 24,6 0,4 50 HLA-A*03 add-on 3F3 3 15 10 24,6 0,4 50 HLA-A*24 add-on 3F2 4 18 12 29,5 0,5 60 HLA-A*68 add-on 2E3 3 15 10 24,6 0,4 50 HLA-B HLA-B*07 add-on 4E4 7 27 18 44,2 0,8 90 HLA-B*39 add-on 4E2 3 15 10 24,6 0,4 50 HLA-B*15 add-on 8E5 3 15 10 24,6 0,4 50 HLA-C HLA-C*04 add-on 6E1 5 21 14 34,4 0,6 70 HLA-C*07 add-on 0F6 8 30 20 49,2 0,8 100 HLA-C*08 add-on 6E7 5 21 14 34,4 0,6 70 HLA-C*15 add-on 5E7 4 18 12 29,5 0,5 60 HLA-DR DRB1*14:01/14:54 0G7 3 15 10 24,6 0,4 50 DRB1*04 add-on 4F1 4 18 12 29,5 0,5 60 DRB1*12 add-on 9F3 4 18 12 29,5 0,5 60 KIR name + + KIR KIR Genotyping 9F1 27 93 62 152,5 2,5 310 KIR HLA Ligand 39Y 7 27 18 44,2 0,8 90 Manufactured by lerup SSP AB www.olerup.com Distributed by lerup www.olerup.com lerup SSP AB is IS 9001:2008 and IS 13485:2003 certified. lerup SSP AB typing kits are CE-marked in accordance with the requirements of the IVD Directive 98/79/EC. lerup SSP HLA Typing Kits are FDA cleared and licensed by Health Canada. SSP-180515-5 2018 CareDx, Inc. All service marks and trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved. LK-10378 Rev. 1 08/16